This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q91.5 | Special Copayment Reduction: V160 | Re-certification cycle: 5 years |
| B. Synonyms | None |
| C. Adult onset | Adult survival possible (few) — The mosaic form has a milder clinical picture than the complete form, and long-term survival is possible. In particular, rare cases surviving to adulthood are reported when the proportion of abnormal cells is low. Phenotypic heterogeneity is large. |
| 1. History | Mosaic cases accumulated after the description of the complete form (1960). A relatively milder clinical picture was recognized. |
| 2. Causes | Mixture of 46/47,+13 cells due to mitotic nondisjunction in the early zygote. |
| 3. Genetics | mos 47,+13[n]/46[n]. The proportion of abnormal cells determines phenotypic severity. Low dependence on maternal age. |
| 4. General epidemiology | About 5% of all trisomy 13. Rarer than the complete and translocation forms. |
| 5. Pathophysiology | Mitotic nondisjunction in the early embryo → a state of cell mixture. The proportion varies under cellular selection pressure. |
| 6. Symptoms | Milder phenotype than the complete form. Lower frequency of holoprosencephaly. Reduced polydactyly and microphthalmia. |
| 7. Signs | Overlaps with signs of the complete form but may be mild. Heterogeneity of signs according to the proportion of abnormal cells. |
| 8. Screening | Sensitivity of NIPT and serum screening may be reduced. Screening may be negative if the proportion of abnormal cells is low. Karyotype if clinically suspected. |
| 9. Diagnosis | Karyotype analysis of many cells. FISH, SNP array. Consider multi-tissue analysis. Beware of false negatives. |
| 10. Treatment | Similar to the complete form, but because survival is higher, the proportion of active supportive treatment increases. |
| 11. Prognosis | Relatively better than the complete form. The proportion of abnormal cells is key to prognosis. Long-term survival is possible. |
| 12. Prevention | Specific prevention of the mosaic form is difficult. Prenatal screening and genetic counseling. Same approach as the complete form. |
| 13. References | Patau K (1960) and 9 others. |
Trisomy 13 mosaic form (mosaic trisomy 13, Q91.5) came to be recognized after Patau described complete trisomy 13 in 1960, as karyotype analysis became widespread and cellular mosaicism, in which normal cells and trisomic cells coexist, began to be observed in some patients with Patau syndrome. In early reports, it was noted that patients with the mosaic form showed a milder clinical picture and longer survival than those with the complete form.
From the 1970s, the spread of G-banding karyotype analysis made systematic classification and documentation of the mosaic form possible. During this period it was established that the trisomy 13 mosaic form arises from mitotic nondisjunction during early embryonic development after fertilization, which is mechanistically distinct from meiotic nondisjunction at the stage of gamete formation.
The trisomy 13 mosaic form has several similarities to and differences from the trisomy 18 mosaic form. The similarities are the mechanism of occurrence by mitotic nondisjunction, phenotypic heterogeneity according to the proportion of abnormal cells, and better survival than the complete form. The difference is that the trisomy 13 mosaic form has been studied relatively less, so data are more limited. In particular, there are insufficient data on how much holoprosencephaly (HPE), the characteristic malformation of trisomy 13, is attenuated in the mosaic form.
Since the 2000s, advances in molecular genetic techniques have increased the precision of diagnosing the mosaic form. In particular, SNP microarrays make it possible to measure the proportion of abnormal cells quantitatively and to confirm whether mosaicism results from a trisomy rescue mechanism. In addition, with reports of rare cases of mosaic trisomy 13 surviving to adulthood, the biological diversity and clinical importance of the mosaic form are being re-examined.
In Korea as well, cases of the trisomy 13 mosaic form are included in the rare disease Special Copayment Reduction V160, and it is a rarely diagnosed subtype along with the complete form. In clinical practice, the possibility of the mosaic form should always be kept in mind, and karyotype analysis that analyzes a sufficient number of cells is needed.
The trisomy 13 mosaic form (Q91.5) results in a state in which normal cells (46 chromosomes) and trisomic cells (47 chromosomes, 3 copies of chromosome 13) coexist, due to mitotic nondisjunction occurring during early embryonic development after the formation of the zygote. This is the fundamental difference from the meiotic nondisjunction form (complete form).
Mitotic nondisjunction occurs from an error in the separation of sister chromatids of chromosome 13 during early cleavage of the zygote. As a result, one daughter cell has 47,+13 and the other has 45,−13. The 45,−13 monosomic cells are disadvantaged for survival and are mostly eliminated, and the 47,+13 trisomic cells and normal cells (46) coexist, maintaining the mosaic state.
The proportion of abnormal cells is determined by the point in embryonic development at which nondisjunction occurs. The earlier it occurs, the higher the proportion of abnormal cells; the later it occurs, the lower the proportion. The proportion of abnormal cells in the mosaic form differs between individuals, and this is the main cause of phenotypic heterogeneity.
Some mosaic forms arise by a mechanism in which normal cells are generated in some cells of a complete trisomic zygote by trisomy rescue. In this case, uniparental disomy (UPD) 13 can occur in the normal-appearing cells. The clinical significance of UPD 13 is not clear to date, but some studies raise the possibility of an association with imprinted genes.
Unlike the complete form, the occurrence of the mosaic form has a low correlation with maternal age. Therefore, the mosaic form can occur in young mothers as well, and the advanced maternal age risk factor applies only weakly to it. The exact cause of the mosaic form is unknown, and no specific risk factors have been established.
The karyotype of the trisomy 13 mosaic form is written as mos 47,XX,+13[n]/46,XX[m] or mos 47,XY,+13[n]/46,XY[m], where n and m are the numbers of analyzed trisomic cells and normal cells, respectively. The proportion of abnormal cells is clinically important.
Proportion of abnormal cells and phenotype: In the trisomy 13 mosaic form, the relationship between the proportion of abnormal cells and phenotype shows an imperfect correlation, similar to the trisomy 18 mosaic form. A higher proportion tends to produce a severe phenotype close to the complete form, but because the distribution of mosaicism differs by tissue, it is difficult to predict the entire clinical course from the proportion in peripheral blood alone.
Tissue-specific mosaicism: The proportion of abnormal cells may differ in specific tissues (e.g., brain, heart). Even if the proportion of trisomic cells in peripheral blood is low, severe malformations may occur if the proportion is high in the brain or heart. Conversely, even if the proportion in peripheral blood is high, the phenotype may be mild if the proportion in vital organs is low. This tissue heterogeneity makes it difficult to predict the phenotype of the mosaic form.
Recurrence risk: The mosaic form also occurs sporadically with normal parental karyotypes, so the recurrence risk is low. However, because the possibility of gonadal mosaicism cannot theoretically be excluded, prenatal genetic diagnosis is recommended in the next pregnancy. Because clear empirical statistics on the sibling recurrence risk of the trisomy 13 mosaic form are limited, about 1% or the age-based risk, whichever is higher, is used.
UPD analysis: In the mosaic form arising by trisomy rescue, UPD 13 may be present in the normal cells. Whether UPD 13 involves clinically important imprinted genes has not been fully established, but some studies suggest mild phenotypic changes associated with maternal UPD 13. UPD analysis may be considered to provide complete clinical information.
The trisomy 13 mosaic form (Q91.5) accounts for about 5% of all Patau syndrome, which is rarer than the complete form (about 80%) and the translocation form (about 10–15%). This is a slightly higher proportion than the trisomy 18 mosaic form (about 2–5%).
The absolute incidence per live birth is very low, making accurate statistics difficult to obtain. Since it is about 5% of the overall frequency of Patau syndrome (about 1/5,000–1/12,000), the mosaic form is estimated at about 1/100,000–1/250,000 births. Because of phenotypic heterogeneity, some mild mosaic forms may go undiagnosed, so the actual frequency may be higher.
Sex distribution and maternal age: Because the mosaic form arises from mitotic nondisjunction, its correlation with maternal age is lower than that of the complete form. It can occur in young mothers as well. The sex distribution may tend toward a female predominance, similar to the complete form, but this is not statistically clear.
Clinical recognition of the mosaic form is lower than that of the complete form. This is because the clinical phenotype is atypical or mild, so Patau syndrome is sometimes not suspected. In particular, mild mosaic forms with a low proportion of abnormal cells present with nonspecific symptoms such as developmental delay, mild malformations, and learning disability, and are sometimes found incidentally during genetic testing.
Because long-term follow-up data on the trisomy 13 mosaic form are limited worldwide, data accumulation through participation in rare disease registries and case registration is needed. In Korea as well, this is an area that needs case registration and long-term follow-up studies at rare disease specialty centers.
The pathophysiology of the trisomy 13 mosaic form, as with the trisomy 18 mosaic form, is the formation of a mixed cell state by mitotic nondisjunction in the early embryo. However, there are additional considerations from the viewpoint of the biological characteristics of chromosome 13 and the malformation pathways of Patau syndrome.
When mitotic nondisjunction occurs in early embryonic development, 47,+13 trisomic cells and 45,−13 monosomic cells are generated. The monosomic cells are disadvantaged for survival and are eliminated, and a mixed state of trisomic cells and normal cells is maintained. The earlier the embryonic stage at which nondisjunction occurs, the more cells belong to the trisomic lineage.
Whether the characteristic holoprosencephaly (HPE) of trisomy 13 occurs, and its severity, are determined by how overexpression of the relevant genes acts during the critical period of forebrain development (4–6 weeks of gestation). The fact that holoprosencephaly occurs less frequently in the mosaic form than in the complete form suggests that holoprosencephaly may be prevented when the proportion of trisomic cells in the brain-forming cell lineage is low or when normal cells are formed by trisomy rescue.
The occurrence of postaxial polydactyly is likewise determined by the proportion of abnormal cells in the limb-forming cell lineage. The lower frequency of polydactyly in the mosaic form than in the complete form is interpreted as due to a higher proportion of normal cells in the cells of the limb developmental pathway.
Trisomy rescue mechanism: The mosaic form may form when normal cells are generated by loss of the extra chromosome 13 in some cells of a complete trisomic zygote. UPD 13 may occur at this time. The clinical effect of UPD 13 is not yet clear, but if imprinted genes are located on chromosome 13, they may affect the phenotype.
Cellular selection pressure: As development proceeds, proliferative competition occurs between normal cells and trisomic cells. In some tissues, normal cells may selectively proliferate, lowering the proportion of trisomic cells. Conversely, in specific tissues, trisomic cells may selectively proliferate, raising the proportion. This complex cellular selection dynamic explains the tissue-specific heterogeneity of the mosaic form.
The clinical symptoms of the trisomy 13 mosaic form (Q91.5) are similar to the features of complete Patau syndrome (Q91.4), but they show a wide spectrum from mild to severe, approaching the complete form, depending on the proportion of abnormal cells. This is the most important clinical feature of the mosaic form.
Central nervous system: Holoprosencephaly (HPE) occurs less frequently than in the complete form. In the mosaic form, holoprosencephaly may be absent, and even when it occurs, it is often relatively mild, such as lobar HPE. Microcephaly and agenesis of the corpus callosum may occur. Intellectual disability and developmental delay are present in almost all mosaic forms, but the degree is often milder than in the complete form.
Facial malformations: Microphthalmia may occur less frequently than in the complete form. Cleft lip and cleft palate may accompany. Severe median facial malformations such as cyclopia and median cleft lip are less common in the mosaic form.
Polydactyly: Postaxial polydactyly may occur less frequently than in the complete form. In some mild mosaic forms, polydactyly is absent.
Cardiovascular system: Cardiac malformations may accompany, but their frequency and severity may be lower than in the complete form. The types of cardiac malformations are VSD, PDA, ASD, etc., similar to the complete form.
Scalp defects: Scalp defects (cutis aplasia) may occur less frequently than in the complete form.
Atypical phenotype of mild mosaic form: In mild mosaic forms with a low proportion of abnormal cells, only mild intellectual disability, growth failure, subtle facial malformations, or mild cardiac malformations may be present, or an atypical phenotype not suspected to be Patau syndrome may be seen. In this case, it is sometimes found incidentally during genetic testing. The possibility of the trisomy 13 mosaic form should always be considered in intellectual disability or developmental delay of unknown cause.
The physical signs of the trisomy 13 mosaic form overlap with those of the complete form but are milder depending on the mosaic proportion. It is impossible to distinguish the mosaic form from the complete form, or to estimate the proportion of abnormal cells, by physical examination alone.
Craniofacial signs: Microcephaly, microphthalmia, cleft lip and cleft palate, low-set ears, etc. may be milder than in the complete form. When holoprosencephaly is absent, severe facial malformations such as cyclopia or median cleft lip are absent.
Scalp defects: Localized skin defects of the scalp may occur but may be less frequent than in the complete form.
Limb, hand, and foot signs: Postaxial polydactyly may be mild or absent. Clubfoot or finger contractures may occur.
Cardiac signs: Heart murmur and cyanosis may accompany, but in mild mosaic forms cardiac malformations may be absent or mild.
Neurological signs: Hypotonia, seizures, and apneic episodes may occur. In the mosaic form, seizures or apnea may appear later or be less severe than in the complete form.
Prenatal ultrasound findings: When the proportion of abnormal cells is low, characteristic findings such as holoprosencephaly or polydactyly may not be observed on prenatal ultrasound, so it may go undetected. When the proportion of abnormal cells is high, ultrasound findings similar to those of the complete form appear.
Karyotype findings: Peripheral blood karyotype analysis shows a mixture of trisomic cells and normal cells. The number of cells analyzed and the proportion of abnormal cells must be stated in the karyotype report.
The key consideration in prenatal screening for the trisomy 13 mosaic form is that screening sensitivity is lower than for the complete form when the proportion of abnormal cells is low.
NIPT (cfDNA): Detection is possible only if the proportion of trisomic cells in the placenta is reflected in the fetal fraction. If the proportion of abnormal cells is low, NIPT may show a negative result. Conversely, even if NIPT is positive in confined placental mosaicism (CPM), the actual fetal karyotype may be normal. If clinical suspicion is strong regardless of the NIPT result, invasive testing is performed.
Maternal serum screening (MSS): In the mosaic form, the abnormal serum marker pattern may be less prominent than in the complete form. If the proportion of abnormal cells in the placenta is low, changes in serum markers may not be observed.
Prenatal ultrasound: In the mosaic form, the characteristic findings of the complete form (holoprosencephaly, polydactyly, microphthalmia) appear only partially or are very subtle, limiting detection. However, when structural abnormalities are found, invasive testing including karyotype analysis is performed.
Postnatal screening: For developmental delay of unknown cause, intellectual disability, or clinical findings suggestive of Patau syndrome in the neonatal period or childhood, karyotype analysis (analysis of many cells) is performed. Even if the karyotype is normal, when clinical suspicion is strong, skin fibroblast FISH, SNP array, etc. are additionally performed.
Consider confined placental mosaicism (CPM): CPM is a situation in which trisomic cells are detected in the placenta but the fetus itself is normal or only partially abnormal. To distinguish CPM from true fetal mosaicism, it helps to perform amniocentesis (fetal cells) and CVS (placental cells) together.
The diagnosis of the trisomy 13 mosaic form follows the same principles as the trisomy 18 mosaic form.
Standard G-banding karyotype analysis: At least 20–30 cells are analyzed from peripheral blood, and when mosaicism is suspected, high-resolution analysis of 50–100 cells is performed. If abnormal cells are observed, the total number of cells analyzed, the number in each cell line, and the proportion of abnormal cells are stated in the report. The presence of trisomy 13 cells must be confirmed to diagnose the mosaic form.
Distinguishing complete, mosaic, and translocation forms: If all cells are trisomic, it is classified as the complete form (Q91.4); if normal cells and trisomic cells coexist, the mosaic form (Q91.5); and if there are 46 chromosomes but a translocation is present, the translocation form (Q91.6). This distinction is essential for prognostic counseling and recurrence risk counseling. Because the proportion of the translocation form is high in trisomy 13, it is important to also exclude the possibility of the translocation form when diagnosing the mosaic form.
FISH: Using a chromosome 13-specific probe, a large number of interphase cells are analyzed to assess the mosaic proportion more accurately.
Chromosomal microarray (CMA): SNP array allows quantification of the mosaic proportion, UPD 13 analysis, and detection of additional genomic imbalances. The proportion of abnormal cells must be about 20–30% or more to be detectable on the array.
Multi-tissue analysis: Even when peripheral blood shows a normal karyotype, if clinical suspicion is strong, additional analysis is performed on skin fibroblasts, buccal mucosa cells, and urine cells.
Treatment of the trisomy 13 mosaic form follows the same principles as the complete form, but because survival is higher, long-term supportive treatment carries greater weight.
Neonatal intensive care: Cardiopulmonary stabilization, apnea management, and seizure control are the priorities. The intensity of invasive treatment is individualized according to the clinical condition and the family's wishes.
Cardiac surgery: In the mosaic form, the indications for cardiac surgery can be considered more actively. The decision on cardiac surgery is made through shared decision-making between the multidisciplinary team and the family.
Seizure management: Seizures are controlled with anticonvulsants (phenobarbital, levetiracetam, etc.). Electroencephalography (EEG) is used to identify the seizure type and establish the treatment plan.
Developmental support and rehabilitation: Developmental intervention through physical therapy, occupational therapy, and speech therapy is started early. Developmental potential is supported as much as possible in connection with special education. In the mosaic form, the likelihood of expecting benefit from developmental intervention is higher than in the complete form.
Visual and hearing rehabilitation: When microphthalmia or visual malformations are present, ophthalmologic evaluation and visual rehabilitation are performed. When hearing loss is present, hearing aids or auditory rehabilitation are provided.
Family support and palliative care: Because the likelihood of long-term survival is higher than in the complete form, family support, linkage to social services, and long-term care planning are important. The palliative care team also participates concurrently to discuss treatment goals and end-of-life planning with the family.
The prognosis of the trisomy 13 mosaic form (Q91.5) is generally better than that of the complete form, but there are large individual differences depending on the proportion of abnormal cells and the clinical phenotype. The most important reason the prognosis of the mosaic form is better than that of complete Patau syndrome is the reduced frequency and severity of holoprosencephaly.
Survival rate: The 1-year survival rate of the mosaic form is significantly higher than the 5–10% of the complete form. Some reports describe cases in which the 3–5-year survival rate of the mosaic form was markedly improved over the complete form. Cases surviving to adulthood are rarely reported.
Causes of death and clinical course: The main causes of death are heart failure, respiratory failure, and apnea, and when holoprosencephaly is absent, acute brain-related death decreases. In surviving children with the mosaic form, intellectual disability, developmental delay, seizures, and visual and hearing impairment persist.
Comparison with the trisomy 18 mosaic form (Q91.1): The trisomy 13 mosaic form (Q91.5) and the trisomy 18 mosaic form (Q91.1) both show a better prognosis than the complete form, but because of the possible presence of a severe brain malformation, holoprosencephaly, the prognosis of the trisomy 13 mosaic form tends to be generally worse than that of the trisomy 18 mosaic form.
Limits of prognostic prediction: It is difficult to predict prognosis accurately from the proportion of abnormal cells alone. The distribution of cells in key organs (brain, heart) is decisive, but this is difficult to measure directly in clinical practice. Therefore, individualized prognostic counseling is needed that comprehensively considers the clinical characteristics of the individual patient (presence of holoprosencephaly, severity of cardiac malformations).
Because the trisomy 13 mosaic form arises from random mitotic errors in early embryonic development, there is no specific method of prevention.
Prenatal screening and diagnosis: In the mosaic form, the sensitivity of NIPT or serum screening may be reduced, but the currently available screening tools are used to the fullest. When structural abnormalities are found on ultrasound, invasive testing is performed immediately.
Genetic counseling: To parents who have delivered a child with the mosaic form, it is explained that the recurrence risk is low, and prenatal genetic diagnosis options for the next pregnancy (NIPT + invasive confirmation) are presented. The phenotypic diversity and prognostic uncertainty of the mosaic form are explained thoroughly.
Long-term follow-up studies and registries: To address the lack of long-term data on the mosaic form, it is important to register cases in rare disease registries and participate in domestic and international collaborative research.
PGT-A: In assisted reproduction, implantation of trisomy 13 embryos can be prevented through PGT-A. However, there is still uncertainty in interpreting the clinical significance of mosaic embryos, so expert counseling is needed.